US 11524013
Treatment of hypercoagulopathy in Cushing's syndrome by administration of glucocorticoid receptor modulators
granted A61KA61K31/4745A61K31/567
Quick answer
US patent 11524013 (Treatment of hypercoagulopathy in Cushing's syndrome by administration of glucocorticoid receptor modulators) held by Corcept Therapeutics Incorporated expires Mon Dec 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Corcept Therapeutics Incorporated
- Grant date
- Tue Dec 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 21
- CPC classes
- A61K, A61K31/4745, A61K31/567, A61K45/06, A61P